Cost Analysis of the Treatment of Schizophrenia in the UK
- PDF / 113,118 Bytes
- 7 Pages / 505 x 720 pts Page_size
- 25 Downloads / 210 Views
Pharmacoeconomics 2000 Apr; 17 (4): 383-389 1170-7690/00/0004-0383/$20.00/0 © Adis International Limited. All rights reserved.
Cost Analysis of the Treatment of Schizophrenia in the UK A Simulation Model Comparing Olanzapine, Risperidone and Haloperidol Stephen Almond1 and Owen O’Donnell2 1 Personal Social Services Research Unit, University of Kent at Canterbury, Canterbury and London School of Economics and Political Science, London, England 2 Department of Economics, University of Kent at Canterbury, Canterbury, England
Abstract
Objective: To compare the costs of 2 atypical drug therapies (olanzapine and risperidone) with one another and with a conventional antipsychotic (haloperidol) in the treatment of schizophrenia. Design and setting: The analysis is based on a simulation model with parameter values taken mainly from clinical trial data in patients with schizophrenia, and was conducted within a UK context. Results: The 3 therapies are approximately cost neutral over a 5-year period (olanzapine £35 701, risperidone £36 590 and haloperidol £36 653). There is evidence of greater efficacy with the atypical drugs [average percentage of 5 years with Brief Psychiatric Rating Scale (BPRS) scores
Data Loading...
